AAN: Using Entire Shape of CBFV Waveform IDs Concussion

Share this content:
AAN: Using Entire Shape of CBFV Waveform IDs Concussion
AAN: Using Entire Shape of CBFV Waveform IDs Concussion

FRIDAY, April 15, 2016 (HealthDay News) -- A machine-learning platform that uses the entire shape of cerebral blood flow velocity (CBFV) waveforms acquired via transcranial Doppler (TCD) imaging is more accurate for diagnosing concussion, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 15 to 21 in Vancouver, Canada.

Robert Hamilton, Ph.D., from Neural Analytics in Los Angeles, and colleagues examined the accuracy of a platform that uses the entire shape of the CBFV waveform in a study involving two groups: a post-injury group of 66 high school contact sports athletes and an age-matched control group (169 high school athletes). Measurements were taken within 12 days of injury; conventional TCD ultrasound measures were compared to morphological analysis performed by the machine-learning platform.

The researchers found that concussed and healthy groups could be differentiated with an area under the receiver operating curve (AUC) of 83 percent (71 and 83 percent sensitivity and specificity, respectively). Lower AUCs were seen for mean velocity, pulsatility index, and cerebrovascular reactivity (55, 53, and 60 percent, respectively).

"This research suggests that this advanced form of ultrasound may provide a more accurate diagnosis of concussion," Hamilton said in a statement. "While more research is needed, the hope is such a tool could one day be used on the sidelines to help determine more quickly whether an athlete needs further testing."

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths